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Despite frequent exposures to a variety of potential triggers, including antigens produced by patho-
gens or commensal microbiota, B-lymphocytes are able to mount highly protective responses to a
variety of threats, while remaining tolerant to self-components. A number of cytokines, signaling
pathways and transcription factors have been characterized to elucidate the mechanisms underly-
ing B cell tolerance to self. It is, however, unclear how the signals received by B-lymphocytes are
converted into complex and sustained patterns of gene expression that can allow production of pro-
tective antibodies and maintain immune tolerance to self-components. Mounting evidence now
suggests an important role for epigenetic mechanisms in modulating and transmitting signals for
B lymphocyte tolerization to self-antigens. It is likely that a better insight into epigenetic regulation
of B cell tolerance will lead to development of gene-speciﬁc therapeutic approaches that optimize
host defense mechanisms to exogenous threats, while preventing development and/or progression
of autoimmune inﬂammatory diseases.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
It is estimated that up to 8% of the population suffer from auto-
immune diseases, such as systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA). Their origin is unknown, but genetic
predisposition has been proposed to play a role in the development
of autoimmune diseases. Whereas a number of susceptibility genes
have been identiﬁed, the failure to explain the pathogenesis of the
gene variants identiﬁed by using only genetic approaches supports
the view that these diseases are multifactorial. Intriguingly, we are
witnessing a progressive rise in the prevalence of autoimmune dis-
eases, particularly in western countries, which is not consistent
with a model of pure genetic susceptibility. There are also observa-
tions showing connections between disease susceptibility and
environmental exposure during intrauterine life or early child-
hood, suggesting that epigenetic factors could play a role in shap-
ing healthy and pathogenic conditions [1,2].
During the last few years, several developments have brought
to attention a differentiated and intricate B lymphocyte contribu-
tion to the control of many aspects of the immune response. Addi-
tionally, the crucial contribution of B-lymphocytes to the
pathogenesis of systemic autoimmune diseases has moved into
the foreground. One realization is that antibodies can mediate tis-
sue injury by a wide variety of distinct mechanisms [3]. In additionto their capacity to secrete autoantibodies, B cells are able to take
part in various functions, such as presentation of antigenic pep-
tides by major histocompatibility complex class II molecules to T
cells [4–6].
The cytokines, signaling pathways, and transcription factors
that underlie B cell tolerance to self remain under investigation.
Despite major advances, the mechanisms that account for disrup-
tion of B cell tolerance in systemic autoimmunity remain under
scrutiny. On the other hand, studies in several species, including
plants, fruit ﬂies, honeybees and rodents, and different model sys-
tems have revealed that diverse biological properties can be af-
fected by epigenetic factors. In humans, epigenetic studies are
pursued in a variety of conditions, including autoimmune diseases
[2]. It has become clear that the epigenetic landscape established
during B cell development guides the impact of signaling pathways
and transcription factors on the functional outcome of cell fate
decisions, and on acquisition and maintenance of immune toler-
ance. This paper will focus on mechanisms of epigenetic regulation
of B cell tolerance to self, and on potential epigenetic alterations
that may underlie break of homeostasis in B lymphocytes, central
stage players in autoimmune disorders.
2. Epigenetic marks during B cell speciﬁcation and
differentiation
B-lymphocytes are generated through several differentiation
steps that lead to the formation of early B cell precursors, pro-B
cells, pre-B cells, immature B cells, terminally differentiated
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Fig. 1. Epigenetic checkpoints during B lymphocyte speciation and differentiation. B-lymphocytes are generated through several differentiation steps that lead to the
formation of early B cell precursors, pro-B cells, pre-B cells, immature B cells, terminally differentiated plasma cells, and memory B cells. Shown are the epigenetic regulators
discussed in this paper. Epigenetically active marks include acetylation of histone 3 at lysine 9 (H3K9ac) and di- and tri-methylation of histone 3 at lysine 4 (H3K4me2 and
H3K4me3). Histone deacetylases include HDAC1 and HDAC2.
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cell progression step is under the inﬂuences of a potent network
of transcription factors speciﬁc for each particular cellular state.
At each transition stage, a new, lineage-speciﬁc genetic program
is activated, and the preceding one extinguished. Mounting evi-
dence indicates that activation of lineage-speciﬁc genes and
repression of inappropriate gene transcription at a particular B
lymphocyte developmental stage is under epigenetic regulation
that operates though four principal mechanisms, namely DNA
methylation, histone modiﬁcation, chromatin remodeling, and reg-
ulation of gene expression by the action of noncoding RNAs,
termed microRNA (Fig. 1).
Initially, commitment to the lymphoid lineage requires the tran-
scription factors Ikaros and PU.1, but the mechanisms by which
they alter the chromatin status of their target genes remain under
scrutiny [7]. For speciﬁcation of common lymphoid progenitors to
the B cell lineage, the transcription factors E2A and EBF1 activate
the expression of genes essential for the formation of pro-B cells;
but it is Pax5 that acts as a master transcription factor for commit-
ment to the B-cell lineage. For example, EBF and E2A contribute to
the CpG demethylation and nucleosomal remodeling of the CD79a
promoter, which is necessary for its transcriptional activation by
Pax5. During B cell development, expression of Pax5 increases in
a stepwise manner, from the early pro-B cell stage up to the mature
B cell stage. It is capable of inducing the expression of a B cell-spe-
ciﬁc genetic program (B cell signaling, adhesion, migration, antigen
presentation and germinal-center B cell formation, as well as tran-
scription factors) and suppressing inappropriate genes of alterna-
tive lineages (secreted proteins, cell adhesion molecules, signals
transducers, and nuclear proteins speciﬁc to erythroid, myeloid
and T cells), thereby ensuring a chief role inmaintaining B cell iden-
tity and differentiation [7]. Not surprisingly, the genes activated by
Pax5 are enriched with epigenetically active marks, such as acety-
lation of histone 3 at lysine 9 (H3K9ac) and di- and tri-methylation
of histone 3 at lysine 4 (H3K4me2 and H3K4me3).
The epigenetic regulation of the Cd19 B cell speciﬁc-gene, which
encodes a cell surface protein that participates in signal transduc-
tion through the BCR and pre-BCR, further illustrates how B cell
lineage-speciﬁc transcription factors cooperate to mediate generegulation during B cell development. Chromatin remodeling of
an upstream enhancer at the Cd19 locus that occurs early in mul-
tipotent progenitors facilitates recruitment of E2A, followed by
binding of EBF and Pax5 during B cell differentiation [8]. Only after
Pax5 binding will the Cd19 promoter be transcriptionally activated.
An additional transcription factor implicated in early B lympho-
poiesis is FOXO-1 whose deletion in mouse models leads to a
developmental block at the pro-B cell stage [9,10]. FOXO1 cooper-
ates with E2A and EBF to orchestrate B cell commitment. During
progression from the pre-pro-B cell to pro-B cell stage, E2A-associ-
ated genes acquire a methyl group at lysine 4 on H3 (H3K4me), a
mark of gene enhancer elements [11]. Following this initial meth-
ylation, EBF and FOXO1 are activated, which leads to histone mod-
iﬁcations, including H3K4me3 on B-cell-specifying genes, such as
Pax5 [11].
Early B cell development requires additional epigenetic regula-
tors, such microRNAs (miRNA). In addition to the role of Ago2
(which encodes a protein essential for microRNA biogenesis and
function) and Dicer (which is important for the entire miRNA net-
work) in B cell development and differentiation, miR-181, miR-
150, and miR-34a appear to target and repress transcripts critical
for genes involved in B cell generation. Recently, characterization
of the microRNAome during lymphopoiesis at the genome-wide
scale led to identiﬁcation of miRNAs that are primed for expression
at different stages of differentiation, including the repressive mark
H3K27me3 associated with gene silencing of lineage-inappropriate
miRNA and the presence of the epigenetically active mark H3K4me
[12]. The observations suggest that, during B cell lineage speciﬁca-
tion, miR-320, miR-191, miR-139 and miR28 act as potential regu-
lators of B cell progression [12].
B cell terminal differentiation is regulated by the mutually
exclusive transcriptional repressors Bcl6 and Blimp-1. After anti-
gen engagement in the germinal center, Bcl6 is upregulated in
some B cells, thereby repressing Blimp-1, which is considered a
master regulator of B cell terminal differentiation into antibody
producing cells. In contrast, Bcl6 blocks the differentiation into
plasma cells, and cells that do not upregulate its expression under-
go differentiation into plasma cells. At the molecular level, Bcl6
interacts with the chromatin remodeling complex Mi-2/NuRD in
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plasma cells via recruitment of the histone deacetylases HDAC1
and HDAC2 [13,14].
In their ﬁnal maturation stages, B cells can give rise to two func-
tionally distinct peripheral populations, follicular (FO) and mar-
ginal zone (MZ) B cells, whose fate decision is functionally
coupled to BCR signaling with autoreactive B cells preferentially
driven into a MZ fate [4,15]. Analysis of conditional Dicer-deﬁcient
mice at late stages of B cell development revealed that miRNA are
important for B cell fate decisions. In their absence, generation of
FO B cells is impaired, MZ B cells are overrepressed, and high titers
of autoreactive antibodies are present in the circulation [16]. Thus,
microRNAs represent an important factor for correct BCR-mediated
B cell development.
3. Chromatin modiﬁcations and locus contraction during
antibody gene joining
Generation of antigen receptors expressed on lymphocytes re-
quires DNA-recombination that assembles gene segments spread
over several megabases of the genome. This process, called V(D)J
recombination, is precisely coordinated throughout lymphocyte
development. In the B lymphocyte lineage, genes that encode
immunoglobulin (Ig) heavy chains (Igh) rearrange ﬁrst, followed
by rearrangement of genes that encode Ig light chains (Igk and
Igl). It is the variable (V), diversity (D) and joining (J) gene seg-
ments that rearrange ﬁrst and require two recombination events
to generate fully recombined alleles. Importantly, D-to-J recombi-
nation precedes recombination of the V region to the preformed
DJ junction to produce VDJ-recombined alleles [17]. Central to
the V(D)J recombination is the recruitment of the recombinases
RAG-1 and RAG-2 to loci destined for rearrangement, followed by
introduction of double-strand breaks at special recombination sig-
nal sequences (RSSs) that ﬂank gene segments to initiate recombi-
nation. The choice of the antigen-receptor gene that will
recombine is determined by accessibility of a locus to the RAG
recombinase, leading to the following order of rearrangements of
the gene encoding the B cell antigen receptor: Igh accessibility pre-
cedes Igk accessibility, and DH segments become accessible before
VH segments.
Regulation of V(D)J recombination relies on developmental-
stage speciﬁc changes in locus accessibility to the RAG-recombi-
nase, including subnuclear relocation, histone modiﬁcations, DNA
demethylation, germline transcription, antisense intergenic tran-
scription, and locus contraction mediated by looping of individual
chromatin domains [18]. Accessibility is controlled by cis-regula-
tory elements within the Ig loci, such as promoters, matrix attach-
ment regions, silencers, and enhancers, where binding of
ubiquitously expressed, lineage-speciﬁc transcription factors, e.g.,
Pax5, E2A, Ikaros, IRF4, or OBF-1, cooperate to establish higher-or-
der chromatin structures that facilitate long-range interactions re-
quired for VH–DJH or Vj–Jj rearrangements [18–20].
As in other cell types, B cell fate commitment is not simply a
consequence of the action of a single transcription factor. Instead,
it depends on a network of regulatory molecules. The transcription
factor STAT5 and the chromatin modiﬁer Ezh2 regulate accessibil-
ity of distal VH gene segments through distinct non-redundant
molecular mechanisms. Ikaros, on the other hand, is essential for
positively regulating VH-to-DJH rearrangement at the Igh locus,
which is the deﬁning hallmark of B cell fate commitment [21].
Through binding to sites in the RAG locus, and regulating histone
acetylation, as well as transcription, Ikaros serves a central func-
tion in Ig gene rearrangement at the pro-B stage by simultaneously
regulating the expression of Rag1 and Rag2 genes, and controlling
VH gene accessibility and compaction of the Igh locus [21].In early studies, chromatin structure has been considered a key
determinant of locus accessibility. Thus, acetylated histones are
present in all antigen-receptor loci, before the initiation of recombi-
nation in the appropriate lymphocyte lineage and at the appropriate
developmental stage {Schatz, 2011 #2}, and rearrangeable loci are
marked with activation-associated histone methylation, such as
di- or trimethylation of histone H3 Lys4 (H3K4me2 or H3K4me3,
respectively). Conversely, the repressive dimethylation of histone
H3 Lys9 (H3K9me2) is diminished before recombination [22].
Recent observations indicate that DJH junctions are selectively
epigenetically marked, become nuclease sensitive and bind RAG
recombinase proteins, which permits DH-associated recombination
signal sequences to initiate the second step of Igh gene assembly
[23]. The studies suggest that VH recombination follows DH recom-
bination because it is only after the formation of DJH junctions that
RAG proteins have ready access to the 50 RSS of DH genes. Several
mechanisms can be considered by which chromatin changes are
restricted to DJH junctions. It is possible that, as large portions of
the DH region are actively maintained in silent chromatin, some
of these heterochromatin-associated enzymes are brought along
with the recombining DH segment. After rearrangement, the DH
promoter is activated by proximity to El and results in activation-
and/or transcription-associated histone modiﬁcations near the DJH
junction [23].
Since the sizes of the Ig loci are huge (2.4–3.2 Mb), rearrange-
ment of distal variable region genes requires that the loci must un-
dergo a physical contraction process. For assembly of the distal V
genes, locus contraction and looping for rearrangement must take
place [18]. Even though the mechanism that controls this contrac-
tion process is unknown, current data suggest that the Ig loci are
organized as loops into rosette-like structures separated by spacer
DNA [24], but the factors that regulate these domains are being
identiﬁed. Whereas the transcription factor Pax5 binds to a repeat
sequence in the distal region of the Igh locus and is believed to par-
ticipate in rearrangement of distal VH genes [25], Polycomb group
(PcG) proteins, including EZH2, CTCF, cohesin and YY1, required for
development and cell proliferation through chromatin-mediated
transcriptional repression and for the epigenetic maintenance of
developmental genes in a silent state, have been suggested to reg-
ulate Ig locus structure and to control Ig gene rearrangements
[24,26–28]. In fact, the 25 amino acid YY1 REPO domain necessary
for YY1 PcG function is critical for B-cell development, and could
have a direct effect on the Igj locus structure needed for normal
rearrangement [29]. In its absence, IgH rearrangements were nor-
mal, but there was a selective, dramatic, skewing of the expressed
Igj repertoire. The fact that the REPO domain interacts with pro-
teins from the condensin and cohesin complexes, and that YY1,
EZH2 and condensin proteins co-localize at numerous sites across
the Igj [29] suggest a direct role for YY1-condensin complexes in
Igj locus structure and rearrangement.
4. Crippled B cell functions in systemic autoimmune diseases
Both in human and in murine models of systemic autoimmune
disease, B cell overactivity is responsible for the hypergammaglob-
ulinemia and the production of a large variety of autoantibodies,
some of which are convincingly involved in the pathogenesis of
immune complex-mediated histological damage [5,30]. Different
factors may contribute to B cell overactivity, including defective
regulatory T cell subsets, excessive help provided by certain T cell
subsets, defective suppression, and overreactivity to cytokines
delivered to B cells in an endocrine, paracrine, or autocrine fashion.
In normal conditions, the V(D)J recombination machinery gen-
erates self-reactive B cells that must be removed from the primary
repertoire in the bone marrow, and, then, from the peripheral B cell
2070 M. Zouali / FEBS Letters 587 (2013) 2067–2073repertoire at the T1 to T2 transition stages, never advancing into
the mature B cell subset. In autoimmune patients, however, pro-
portions of self-reactive B cells in the mature naive B cell compart-
ment are increased, as compared with normal controls [30,31].
Longevity factors, such as BAFF, have been shown to play a critical
role in this process, with high serum levels of BAFF enhancing sur-
vival of self-reactive immature B cells and promoting their entry
into the mature B cell pool [32].
As a result, B cells are hyperresponsive to a variety of stimuli,
with enhanced proliferation to polyclonal activators, increased
anti-IgM and -IgD mediated intracellular Ca2+ responses, enhanced
anti-IgM-induced protein tyrosine phosphorylation, and decreased
FcgRIIb1 inhibition of BcR signaling [33,34]. Patients also have in-
creased proportions of B cells expressing activation markers, such
as CD86, in both small ‘‘resting’’ and large ‘‘activated’’ B cells;
and the abnormal B cell activation does not appear to reﬂect dis-
ease activity; nor does it arise from drug treatment effects, sug-
gesting that it reﬂects an intrinsic B cell defect [35]. In lupus, for
example, evidence gathered from the study of both the human dis-
ease and its murine models suggests that B cells may be intrinsi-
cally defective. In contrast to normal B cells, freshly isolated
lupus B cells display a higher epitope density of cell-surface
CD40, CD86, BAFF-R and spontaneously produce increased
amounts of cytokines (IL-10, IL-6). In addition, unmanipulated lu-
pus B cells display aberrant BcR-induced cell signaling events,
which may contribute to the abnormal function of B cells [33,34].
5. Impaired B cell tolerance to self in systemic autoimmunity
Several observations indicate that there are fundamental disor-
ders of, at least, two tolerance mechanisms in the B cell compart-
ment of patients. The ﬁrst important mechanism that is
reportedly deﬁcient in systemic autoimmunity is clonal anergy
[36], which normally silences autoreactive B cells and renders
them tolerant. The second altered mechanism is receptor editing,
which enables autoreactive B cells to undergo successive Ig gene
rearrangements and extinguishes their reactivity with self-anti-
gens [37]. Patients with autoimmune diseases, including RA and
SLE, fail to efﬁciently remove autoreactive B cells at both early
and mature tolerance checkpoints, in the bone marrow and in
the periphery, and exhibit alterations of receptor editing [38–41].
It is easy to envision that impaired receptor editing can result in
ineffective silencing of B cells that have acquired autoreactive
receptors. It is also conceivable that this altered tolerance may pro-
mote disease by an uncontrolled creation of autoreactive antibod-
ies. Studies of autoimmune susceptibility loci also suggest that
impairment of receptor editing may be a major mechanism
through which anti-nuclear antibodies arise [42,43].
Further studies disclosed that altered receptor editing can con-
tribute to the pathogenesis of autoimmune diseases in human
through at least two different mechanisms [41]. Whereas reduced
secondary Ig gene rearrangements may result in ineffective silenc-
ing of B cells, exacerbation of receptor editing can give rise to the
emergence of autoreactive receptors from clones that were initially
devoid of autoreactivity. Both alterations can promote the patho-
genesis of autoimmune diseases by favoring the uncontrolled
emergence and/or persistence of autoreactive B cell clones.
6. Impact of post-translational modiﬁcations on B cell
homeostasis
Several observations point to the existence of an altered tran-
scriptional regulation in autoreactive lymphocytes, with increased
levels and types of defective transcripts relative to normal individ-
uals, an abnormality that could alter lymphocyte functions. Thus,studies of forkhead transcription factors (FOXO) that regulate cell
proliferation and activation, cell survival, and B cell class-switch
recombination revealed that FOXO1 transcript levels are decreased
in SLE patients with active disease activity [44], suggesting that
deregulation in gene expression may be connected to the develop-
ment of tissue damage mediated by the over-activation of autore-
active B lymphocytes.
Another highly speciﬁc post-translational mechanism by which
the immune response can set the balance between immunity and
tolerance is ubiquitination. Recently, identiﬁcation and character-
ization of numerous ubiquitin-modifying enzymes has facilitated
progress in understanding the roles of ubiquitination/deubiquiti-
nation. One of them, A20, also known as tumor necrosis factor a-
induced protein 3 (TNFAIP3), is able to restrict and terminate
inﬂammatory responses through modulation of the ubiquitination
status of central components in NF-jB, interferon regulatory factor
(3IRF3), and apoptosis signaling cascades. Indications that A20 may
play important roles in adaptive immunity and in immune toler-
ance derive from genetic studies that implicate A20 as a suscepti-
bility gene for human lupus [45,46] and RA [47]. In mice, B cell-
speciﬁc expression of A20 was found to restrict CD40 and BCR re-
sponses, terminate CD40-triggered NF-jB signals, limit B cell sur-
vival, and prevent autoimmunity [48]. Conversely, B cell-speciﬁc
loss of A20 expression led to increased numbers of autoantibody-
producing cells that could be linked to an increased resistance of
A20-deﬁcient B cells to physiological apoptosis and escape of auto-
reactive B cells from tolerance. It is possible that A20 expression in
B cells regulates germinal center B cell selection and B cell activa-
tion, thereby modulating key aspects of B cell tolerance. A second
group of investigators found that A20 was required for the normal
differentiation of marginal zone B and B1 cell subsets [49]. Loss of
A20 in B cells lowered their activation threshold and enhanced
proliferation and survival in a gene-dose-dependent fashion, cul-
minating in the presence of class-switched, tissue-speciﬁc autoan-
tibodies. It will be important to determine if such events also take
place in human cells and their relevance to human autoimmune
diseases.
7. An epigenetic basis for distorted Ig gene rearrangements in
autoimmunity
Several molecular mechanisms could account for generation of
the skewed Igj repertoire seen in autoimmune patients [37–41].
Based on results of functional assays with reporter gene constructs,
a cluster of four DNase I-hypersensitive sites residing in the inter-
vening sequence between Vj genes and the Jj region was termed
silencer in the intervening sequence (Sis) [50]. Subsequently, Sis
was found to be a multifunctional cis-acting element involved in
subnuclear targeting of germline Ig sequences in cis and in trans,
as well as in speciﬁcation of the repertoire in rearranging alleles
[51]. Intriguingly, Sis/ mice exhibit a skewed Igj repertoire with
a markedly decreased distal and enhanced proximal Vj gene usage
for primary rearrangement, and a reduced occupancy of Ikaros and
CCCTC-binding factor (CTCF) in the Vj–Jj intervening sequence
[51]. Investigation of the in vivo function of the CTCF DNA-binding
factor in B cell development revealed that CTCF limits interactions
of j enhancers with proximal Vj genes, and prevents inappropriate
interactions between these enhancers and elements outside the Igj
locus [52]. In CTCF/ mice, there was no change in IgH rearrange-
ment, but a skewed Igj rearrangement, with an increased proximal
and decreased distal Vj gene rearrangement, as seen in B cells of
autoimmune patients [38,41]. Since CTCF can limit interactions of
the Igj enhancers with proximal Vj genes [52], the multifunctional
Sis element, able to specify repertoire development and hetero-
chromatin localization to Ig genes, could bias proximal Vj versus
An experimental modelTwo lupus syndromes in human
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Fig. 2. Alteration of DNA methylation is a hallmark of lupus syndromes. Patients with idiopathic lupus, but also with rheumatoid arthritis, exhibit globally hypomethylated
DNA. As discussed in this article, they show impaired rearrangements of their antibody genes, altered B cell tolerance to self, and autoreactivity. In patients with drug-induced
lupus, subjects who take medications that act on DNA methylation – such as the hypertensive drug hydralazine – may develop symptoms indistinguishable from idiopathic
lupus [60]. In animal models, hydralazine inhibits DNA methylation by blocking the activity of DNA methyltransferase 1 (DNMT1). This inhibition results in subversion of
receptor editing in immature B cells, loss of tolerance, and the emergence of circulating autoantibodies to native DNA and to nucleosomes [56].
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perhaps by controlling CTCF and Ikaros binding in the Vj–Jj inter-
vening sequence.
Also of interest is the implication of cohesin proteins in Ig rear-
rangement. Condensin and cohesin complex proteins regulate
chromosome contraction and cohesion during mitosis and meiosis.
They can mediate long-distance chromosomal interactions. As con-
densin I is involved in the process of physically compacting DNA in
the presence of hydrolysable ATP [53], condensin complex proteins
may also participate in bringing V genes in the Ig locus into close
proximity with D and J gene segments. In this context, the REPO
domain, known to be able to recruit PcG proteins to DNA, physi-
cally interacts with condensin and cohesin proteins involved in
large-scale chromosomal structures. Cohesin proteins have been
implicated in Ig locus structure and rearrangement as well as T-cell
receptor rearrangement [27,28]. It is intriguing to postulate that
the condensing/cohesin complex may be functioning abnormally
in patients with autoimmune diseases.
8. Epigenetic modiﬁers underlying impaired B cell tolerance
One mechanism that may account for the phenotype of B cells
of patients with autoimmune diseases (overactivation, increased
levels of CD95 and decreased levels of CD22,. . .) is an altered chro-
matin structure, in part as a result of an imbalance of histone acet-
ylation and or methylation. It can be hypothesized that deﬁcient
acetylation and/or methylation exist and result in skewed gene
expression in autoimmune B cells. It will be useful to test whether
anti-IgM treatment of human B cells from patients and control
individuals leads to dynamic changes in histone H3 lysine acetyla-
tion and whether it affects the status of chromatin histone lysine
methylation, particularly histone H3 lysine 4 dimethylation
(H3K4me2) and lysine 9 dimethylation (H3K9me2). It will also
be useful to determine whether altered expression of CD40, IL-
10, BAFF-R and C86 is associated with a relative under-acetylation,
and whether increasing histone acetylation, by inhibiting histonedeacetylase activity, might correct the disorder. The possibility that
aberrant expression of the encoding genes in B cells reﬂects
skewed gene expression because of altered acetylation of genes
could be tested by probing the capacity of histone acetylation
inhibitors to reverse autoimmune disorders.
As several studies indicate, it is conceivable that impaired
receptor editing in autoimmune diseases could result in ineffective
silencing of B cells that have acquired autoreactive receptors
[31,38,39,41,54,55]. Further insight into the molecular basis of
inefﬁcient editing as a potential cause of autoimmunity comes
from studies based on investigation of the effect of hydralazine,
an anti-hypertensive drug that triggers lupus in humans, on
receptor editing [56]. Hydralazine is a non-nucleoside analog that
inhibits DNA methylation by blocking the activity of DNA methyl-
transferase 1 (DNMT1). This enzyme is the most abundant DNA
methyltransferase in mammalian cells. It can also be blocked by
treatment with extracellular signal-regulated kinase/mitogen-acti-
vated protein kinase (ERK–MAPK) inhibitors [57]. Studies based on
mice harboring human transgenic Igs revealed that, by interfering
with DNMT1, hydralazine or ERK–MAPK inhibitors reduce DNA
methylation, impair receptor editing in bone marrow immature B
lymphocytes and contribute to generation of pathogenic autoreac-
tivity [56]. The data also support the view that epigenetic altera-
tions contribute to exacerbated activation or deregulation of the
mechanisms that maintain tolerance to self-antigens in patients
with lupus, a systemic autoimmune disease that can be triggered
by medications taken to treat a variety of conditions (Fig. 2). Future
studies will determine whether other drugs and xenobiotics that
trigger autoimmunity in humans also can act through similar
mechanisms.
9. Conclusions
Advances in genome-wide methods and high-throughput
sequencing techniques are providing key information on the
epigenome, and are opening up new lines of research into the
2072 M. Zouali / FEBS Letters 587 (2013) 2067–2073elucidation of the epigenetic mechanisms that shape B cell devel-
opment. Investigation of epigenetic regulation of B lymphocyte tol-
erance to self is at early stages, and several exciting areas for future
research remain to be explored. It remains unclear whether B lym-
phocytes at different developmental stages differ in their epige-
netic landscape, and whether there is a speciﬁc ‘‘epigenetic
signature’’ for self-reactive and tolerant B cells. In future research,
conditional gene inactivation in mice should reveal the role of epi-
genetic marks during B cell development and tolerance.
It will be important to extend epigenetic analysis to human
lymphocytes, which differ in several respects from rodent cells,
including investigation of the role of their epigenetic regulation
in autoimmune disease states. Remarkably, many single nucleotide
polymorphisms associated with autoimmune/inﬂammatory dis-
eases were found in regulatory regions that are subject to epige-
netic regulation [58,59]. Naturally, epigenetic therapy of
inﬂammatory diseases has the potential to be gene-speciﬁc, while
exhibiting sustained effects that hold promise for inducing long-
term disease remission [2]. Thus, studies of miRNAs as master gene
regulators are opening new avenues to decipher the origin of auto-
immune diseases and to design novel treatment strategies. Differ-
ent miRNAs have been found to be altered in autoimmune
diseases, depending on factors, such as variations in cell popula-
tion, biological specimens analyzed, technology employed, and
expertise of the investigators. Translation of the knowledge on
miRNAs from the animal models to humans could lead to initiation
of clinical trials in autoimmune diseases.
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